Bimekizumab for treating moderate to severe hidradenitis suppurativa

^*Corresponding author for this work

Research output: Book/Report › Commissioned report

Original language	English
Publisher	National Institute for Health and Care Excellence
Commissioning body	National Institute for Health and Care Excellence
Publication status	Published - 7 Oct 2024

Access to Document

@book{341661192b7c42089bab1a4767e5bf46,

title = "Bimekizumab for treating moderate to severe hidradenitis suppurativa",

author = "Joseph Lord and Perry, {Mark Christopher} and Ros Wade and Melissa Harden and Walton, {Matthew James} and Simmonds, {Mark Crawford}",

year = "2024",

month = oct,

day = "7",

language = "English",

publisher = "National Institute for Health and Care Excellence",

}

TY - BOOK

T1 - Bimekizumab for treating moderate to severe hidradenitis suppurativa

AU - Lord, Joseph

AU - Perry, Mark Christopher

AU - Wade, Ros

AU - Harden, Melissa

AU - Walton, Matthew James

AU - Simmonds, Mark Crawford

PY - 2024/10/7

Y1 - 2024/10/7

M3 - Commissioned report

BT - Bimekizumab for treating moderate to severe hidradenitis suppurativa

PB - National Institute for Health and Care Excellence

ER -